Skip to main content
SpringerLink
Log in

Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The aim of the present study was to investigate the relative bioavailability and bioequivalence of a new tablet formulation of metformin hydrochloride with reference to a standard product in healthy Chinese adult male volunteers. Two randomized, comparative, two-way crossover studies were therefore conducted. In study 1, which was a single-dose study, 20 subjects received 1000 mg metformin hydrochloride lest product extended-release (MXR) tablets followed by the same amount of metformin hydrochloride reference product immediate-release (MIR) tablets with a 7-day washout period between the two doses. In study 2, which was a multiple-dose study, 22 subjects received MXR 1000 mg/d for 9 consecutive days followed by MIR 1000 mg/d with a 14-day washout period between the doses of the test and reference product. The serum metformin concentrations were monitored using a selective and sensitive high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection. The pharmacokinetic parameters were calculated using a 3P97 program. Analysis of variance (ANOVA) of the half-life of the absorption phase (t1/2ka), the half-life of the elimination phase (t1/2kc) and the mean retention time (MRT) and the Wilcoxon Signed Rank test of Tmax for the two preparations were significantly different. A significant difference was found in the ANOVA for Cmax in the single-dose study, while this was not the case in the multiple-dose study. Two one-sided t-tests showed that there were no significant differences in the area under the concentration-time curve (AUC) values between the two formulations. The present study indicates that the test preparation was bioequivalent to the reference preparation when both MXR and MIR were investigated in healthy Chinese adult male volunteers. And on the basis of the mean AUC0−t, AUC0−∞ and AUCss, the relative bioavailability of the MXR was found to be 107.80%, 111.89% and 110.61% respectively compared with MIR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scheen A.J., Lefebvre P.J. (1998): Oral antidiabetic agents. A guide to selection. Drugs, 55, 225–236.

    Article  CAS  PubMed  Google Scholar 

  2. DeFronzo R.A., Goodman A.M., the Multicenter Metformin Study Group. (1995): Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med., 333, 541–549.

    Article  CAS  PubMed  Google Scholar 

  3. Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf J.L. (1997): Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med., 103, 491–497.

    Article  CAS  PubMed  Google Scholar 

  4. Reaven G.M., Johnston P., Hollenbeck C.B., Skowronski R., Zhang J.C., Goldfine I.D., Chen Y.D. (1992): Combined metformin- sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycémie control. J. Clin. Endocrinol. Metab., 74, 1020–1026.

    Article  CAS  PubMed  Google Scholar 

  5. Campbell I.W. (1985): Metformin and the sulphonylureas: the comparative risk. Horm. Metab. Res. (Suppl). 15, 105–111.

    CAS  Google Scholar 

  6. Stumvoll M., Nurjhan N., Peniello G., Dailey G., Gench J.E. (1995): Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 333, 550–554.

    Article  CAS  PubMed  Google Scholar 

  7. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M.; Diabetes Prevention Program Research Group. (2002): Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 346, 393–403.

    Article  CAS  PubMed  Google Scholar 

  8. Turner R., Cull C., Holman R. (1996): United Kingdom Prospective Diabetes Study (UKPDS) 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann. Intern. Med., 124 (1 pt 2), 136–145.

    CAS  PubMed  Google Scholar 

  9. Marchetti P., Navalesi R. (1989): Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin. Pharmacokinet., 16, 100–128.

    Article  CAS  Google Scholar 

  10. Bailey C.J., Turner R.C. (1996): Metformin. New Engl. J. Med., 334, 574–579.

    Article  CAS  PubMed  Google Scholar 

  11. Fujioka K., Pans M., Joyal S. (2003): Glycemie control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther., 25, 515–529.

    Article  CAS  PubMed  Google Scholar 

  12. Hebden J.M., Gilchrist P.J., Blackshaw E.,Frier M.E., Perkins A.C., Wilson CG., Spiller R.C. (1999): Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit formulations. Eur. J. Gastroenterol. Hepatol., 11, 1379–1385.

    Article  CAS  PubMed  Google Scholar 

  13. Huupponen R., Ojala-Karlsson P., Rouni J. Koulu M. (1992): Determination of metformin in plasma by high-performance liquid chromatography. J. Chromatogr., 583, 270–273.

    Article  CAS  PubMed  Google Scholar 

  14. Caille G., Laçasse Y., Raymond M., Landnault H., Perrotta M., Picirilh G., Thiffault J., Spenard J. (1993): Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. Biopharm. Drue Dispos., 14, 257–263.

    Article  CAS  Google Scholar 

  15. Gusler G., Gorsline J., Levy G, Zhang S.Z., Weston I.E., Naret D., Berner B. (2001): Pharmacokinetics of metformin gastricretentive tablets in healthy volunteers. J. Clin. Pharmacol., 41, 655–661.

    Article  CAS  PubMed  Google Scholar 

  16. Cullen E., Liao J., Lukacsko P., Niecestro R., Friedhoff L. (2004): Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharm. Drug. Dispos., 25, 261–263.

    Article  CAS  PubMed  Google Scholar 

  17. Depomed Corp. (2004): Metformin extended release — DepoMed: metformin, metformin gastric retention, metformin GR. Drugs RD, 5, 231–233.

    Article  Google Scholar 

  18. Chow S.C., Liu J.P. (1992): Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker. Inc.

    Google Scholar 

  19. FDA. (1992): FDA Guidelines. Rockville, MD: Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs, 1 July.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, Anhui Medical University, 230032, Hefei, People’s Republic of China

    Jun Li, Yong Jin, Ting-Yu Wang, Xiong-Wen Lü & Yuan-Hai Li

Authors
  1. Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ting-Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiong-Wen Lü
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuan-Hai Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, J., Jin, Y., Wang, TY. et al. Relative bioavailability and bioequivalence of metforphin hydrochloride extended-released and immediate-released tablets in healthy Chinese volunteers. Eur. J. Drug Metabol. Pharmacokinet. 32, 21–28 (2007). https://doi.org/10.1007/BF03190986

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190986

Key words

Search

Navigation